Skip to main content


We're creating a new version of this page. See preview

  • Poster presentation
  • Open Access

Lower toxicity and higher efficacy: a study on a novel fully human anti-EGFR antibody

  • 1 and
  • 1
Journal for ImmunoTherapy of Cancer20153 (Suppl 2) :P241

  • Published:


  • Cetuximab
  • Lower Toxicity
  • Xenograft Mouse Model
  • Lower EGFR
  • EGFR Expression

We generated a novel fully human anti-EGFR antibody showed lower toxicity and higher efficacy in the preclinical, toxicological and pharmacological studies when compared to a commercial drug Cetuximab. In this research, we aimed to understand the probably mechanism.

Firstly, the mAb prefers binding to higher expression of EGFR. Its binding avidity on IgG form of the mAb to EGFR was equivalent to Cetuximab, while the Fab affinity was significantly lower. As a result, Higher EGFR expression tissues like tumor obtained the equivalent efficacy as Erbitux, while normal tissues with lower EGFR expression consequently showed lower toxicity.

Secondly, the new mAb had higher concentration in tumor tissue than Erbitux. The accumulation of antibody in tumor local might induce stronger ADCC effect, and resulted in higher anti-tumor efficacy than Erbitux in a Hu-WBC NOD SCID xenograft mice model.

Authors’ Affiliations

Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, People's Republic of China


© Qiu and Wang 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.